Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 1, 2010, Pages 294-298

  Angibaud, Patrick ^a   Emelen, Kristof Van ^b   Decrane, Laurence ^a   Brandt, Sven van ^b   Holte, Peter ten ^b   Pilatte, Isabelle ^a   Roux, Bruno ^a   Poncelet, Virginie ^a   Speybrouck, David ^a   Queguiner, Laurence ^a   Gaurrand, Sandrine ^a   Mariën, Ann ^c   Floren, Wim ^c   Janssen, Lut ^c   Verdonck, Marc ^b   Dun, Jacky van ^c   Gompel, Jacky van ^b   Gilissen, Ron ^b   Mackie, Claire ^b   Jardin, Marc Du ^b   Peeters, Jozef ^b   Noppe, Marc ^b   Hijfte, Luc Van ^a   Freyne, Eddy ^c   Page, Martin ^c   Janicot, Michel ^c   Arts, Janine ^c   more..

^a Ortho Biotech Oncology Research and Development   (France)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Ortho Biotech Oncology Research and Development   (Belgium)

Author keywords

Anti cancer agents; HDAC inhibitors; Histone deacetylase; Petasis; Pyrimidylhydroxamic acid

Indexed keywords

2 PIPERAZINYL 5 PYRIMIDYLHYDROXAMIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; R 306465; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; NONHUMAN; OVARY CARCINOMA; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; MICE; MICE, NUDE; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 72049113304     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.118     Document Type: Article

References (26)

1. Johnstone R.W. Nat. Rev. Drug Disc. 1 (2002) 287
2. Grant S., Easley C., and Kirkpatrick P. Nat. Rev. Drug Disc. 6 (2007) 21
3. Ten Holte P., van Emelen K., Janicot M., Jong P.C., de Bono J.S., and Arts J. In: Bradbury R. (Ed). Top. Med. Chem Vol. 1 (2007), Springer, Berlin, Heidelberg 293-331
4. Bolden J.E., Peart M.J., and Johnstone R.W. Nat. Rev. Drug Disc. 5 (2006) 769
5. Monneret C. Anticancer Drugs 18 (2007) 363
6. Paris M., Porcelloni M., Binashi M., and Fattori D. J. Med. Chem. 51 (2008) 1505
7. Prince H.M., Bishton M.J., and Harrison S.J. Clin. Cancer Res. 15 (2009) 3958
8. Marks P.A. Oncogene 26 (2007) 1351
9. Marks P.A., and Breslow R. Nat. Biotechnol. 25 (2007) 84
10. Gimsing P. Expert Opin. Investig. Drugs 18 (2009) 501
11. Atadja P. Cancer Lett. 280 (2009) 233
12. Budillon A., Di Genarro E., Bruzzese F., Rocco M., Manzo G., and Caraglio M. Rec. Patents Anticancer Drug Disc. 2 (2007) 119
13. Kazantsev A.G., and Thompson L.M. Nat. Rev. Drug Disc. 7 (2008) 854
14. Sun Y., and Reddy P. Curr. Enz. Inh. 3 (2007) 207
15. Glauben R., Sonnenberg E., Zeitz M., and Siegmund B. Cancer Lett. 280 (2008) 154
16. Arts J., Angibaud P., Mariën A., Floren W., Janssens B., King P., van Dun J., Janssen L., Geerts T., Tuman R.W., Johnson D.L., Andries L., Jung M., Janicot M., and Van Emelen K. Br. J. Cancer 97 (2007) 1344
17. Thermodynamic solubility was determined at different pHs by accurately weighting around 2.5 mg of compound, attempting to dissolve it in phosphate-citrate buffers and filtering (if necessary) over a filter disc. An aliquot of the filtrate was diluted with an appropriate solvent (0.1 N HCl/acetonitrile, 1/1) and submitted for concentration measurement using a generic UPLC method.
18. Petasis N.A., Goodman A., and Zavialov I.A. Tetrahedron 53 (1997) 16463
19. Angibaud P., Arts J., Van Emelen K., Poncelet V., Pilatte I., Roux B., Van Brandt S., Verdonck M., DeWinter H., Ten Holte P., Marien A., Floren W., Janssens B., Van Dun J., Aerts A., Van Gompel J., Gaurrand S., Queguiner L., Argoullon J.M., Van Hijfte L., Freyne E., and Janicot M. Eur. J. Med. Chem. 40 (2005) 597
20. Mai A., Esposito M., Sbardella G., and Massa S. Org. Prep. Proced. Int. 33 (2001) 391
21. Histone Deacetylase assays on a pool of HDAC enzymes obtained from a nuclear HeLa cell extract or on HDAC isoforms were performed at Reaction Biology Corporation (www.reactionbiology.com, Malvern PA) using the 'Spectrum' assay platform.
22. Van Brandt, S.F.A.; Van Emelen, K.; Angibaud, P.R.; Marconnet-Decrane, L.F.B. WO2006/010749, 2006. Enzymatic test conditions reported page 49 and cellular antiproliferative test conditions described pages 49-50 were slightly modified to adapt to 384 well plates.
23. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., and Pavletich N.P. Nature 401 (1999) 188
24. Frizzle M.J., Caille S., Marshall T.L., McRae K., Nadeau K., Guo G., Wu S., Martinelli M.J., and Moniz G.A. Org. Process. Res. Dev. 11 (2007) 215
25. Belien A., De Schepper S., Floren W., Janssens B., Marien A., King P., and Van Dun J. Mol. Cancer Ther. 5 (2006) 2317
26. Glaser K.B., Li J., Staver M.J., Wei R.Q., Albert D.H., and Davidsen .K. Biochem. Biophys. Res. Commun. 310 (2003) 529